Auro Laboratories Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹113.1
- Today's High:
- ₹119.05
- Open Price:
- ₹119.05
- 52W Low:
- ₹52.5
- 52W High:
- ₹137
- Prev. Close:
- ₹119.05
- Volume:
- 9777
Company Statistics
- Market Cap.:
- ₹530.70 million
- Book Value:
- 40.354
- Revenue TTM:
- ₹464.03 million
- Operating Margin TTM:
- 13.98%
- Gross Profit TTM:
- ₹186.97 million
- Profit Margin:
- 11.09%
- Return on Assets TTM:
- 11.79%
- Return on Equity TTM:
- 22.8%
Company Profile
Auro Laboratories Limited had its IPO on under the ticker symbol 530233.
The company operates in the Other sector and Other industry. Auro Laboratories Limited has a staff strength of 0 employees.
Stock update
Shares of Auro Laboratories Limited opened at ₹119.05 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹113.1 - ₹119.05, and closed at ₹114.6.
This is a -3.74% slip from the previous day's closing price.
A total volume of 9,777 shares were traded at the close of the day’s session.
In the last one week, shares of Auro Laboratories Limited have slipped by -11.16%.
Auro Laboratories Limited's Key Ratios
Auro Laboratories Limited has a market cap of ₹530.70 million, indicating a price to book ratio of 2.0985 and a price to sales ratio of 1.1327.
In the last 12-months Auro Laboratories Limited’s revenue was ₹464.03 million with a gross profit of ₹186.97 million and an EBITDA of ₹75.02 million. The EBITDA ratio measures Auro Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Auro Laboratories Limited’s operating margin was 13.98% while its return on assets stood at 11.79% with a return of equity of 22.8%.
In Q3, Auro Laboratories Limited’s quarterly earnings growth was a positive 56% while revenue growth was a positive 40.8%.
Auro Laboratories Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 10.2421
- PEG
Its diluted EPS in the last 12-months stands at ₹8.256 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Auro Laboratories Limited’s profitability.
Auro Laboratories Limited stock is trading at a EV to sales ratio of 0.9258 and a EV to EBITDA ratio of 5.0856. Its price to sales ratio in the trailing 12-months stood at 1.1327.
Auro Laboratories Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹559.94 million
- Total Liabilities
- ₹181.31 million
- Operating Cash Flow
- ₹-50814000.00
- Capital Expenditure
- ₹40.74 million
- Dividend Payout Ratio
- 0%
Auro Laboratories Limited ended 2024 with ₹559.94 million in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹559.94 million while shareholder equity stood at ₹342.01 million.
Auro Laboratories Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹181.31 million in other current liabilities, 62325000.00 in common stock, ₹279.68 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹17.87 million and cash and short-term investments were ₹115.02 million. The company’s total short-term debt was ₹44,000,000 while long-term debt stood at ₹17.58 million.
Auro Laboratories Limited’s total current assets stands at ₹356.62 million while long-term investments were ₹0 and short-term investments were ₹90.85 million. Its net receivables were ₹124.05 million compared to accounts payable of ₹0 and inventory worth ₹117.56 million.
In 2024, Auro Laboratories Limited's operating cash flow was ₹-50814000.00 while its capital expenditure stood at ₹40.74 million.
Comparatively, Auro Laboratories Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹114.6
- 52-Week High
- ₹137
- 52-Week Low
- ₹52.5
- Analyst Target Price
- ₹
Auro Laboratories Limited stock is currently trading at ₹114.6 per share. It touched a 52-week high of ₹137 and a 52-week low of ₹137. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹91.94 and 200-day moving average was ₹77.35 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5919.8% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Auro Laboratories Limited
Similar Industry Stocks (Other)
Most Active
Top Gainers
Top Losers
About
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories Limited was incorporated in 1989 and is based in Mumbai, India.